Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
100

Summary

Conditions
  • Nasal Chondromesenchymal Hamartoma
  • Ciliary Body Medulloepithelioma
  • Cystic Nephroma
  • DICER1 Syndrome
  • Embryonal Rhabdomyosarcoma
  • Sertoli-Leydig Cell Tumor
  • Neuroblastoma
  • Nodular Hyperplasia of Thyroid
  • Pineoblastoma
  • Wilm's Tumor
  • Pituitary Cancer
  • Pleuropulmonary Blastoma
  • Renal Sarcoma
Type
Observational
Design
Observational Model: CohortTime Perspective: Other

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Description

PPB is a rare cancer of the lung presenting in early childhood, mostly commonly from birth to age ~72 months. PPB occurs within the lung or between the lung and the chest wall. There are three primary forms of PPB called Types I, II, and III PPB. PPB is related to an underlying change/mutation in a ...

PPB is a rare cancer of the lung presenting in early childhood, mostly commonly from birth to age ~72 months. PPB occurs within the lung or between the lung and the chest wall. There are three primary forms of PPB called Types I, II, and III PPB. PPB is related to an underlying change/mutation in a gene called DICER1 which impacts gene expression and cell growth. DICER1 mutations may also lead to the development of other tumors in children and adults. The International PPB/DICER1 Registry offers information based on previous data from Registry participants and the medical literature and collaborative efforts with international rare tumor groups. Retrospective and real-time central pathology review is encouraged. Therapy decisions remain at the discretion of the treating institution. Children with Type I PPB require surgery and sometimes chemotherapy. Therapy decisions are the responsibility of the treating institution. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for Type I PPB patients. Chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Children with Types II and III PPB, require surgery, chemotherapy and sometimes radiation therapy. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered.

Tracking Information

NCT #
NCT03382158
Collaborators
  • Children's National Research Institute
  • Washington University School of Medicine
  • ResourcePath, LLC
  • Beijing Children's Hospital
  • University of Cambridge
  • Emory University
  • Dana-Farber Cancer Institute
Investigators
Principal Investigator: Kris Ann P Schultz, MD Children's Minnesota